Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | BCL2 | P10415 | 1/20 | 0.59 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68224 | 0.83 | ALOX15 (0.54) | HPGDMEN1CYP3A4ALOX15KMT2A | |
| Clorophene SCHEMBL28270037 | 0.83 | MEN1 (0.81) | HPGDMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL8406689 | 0.83 | HTT (0.53) | HPGDMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL4813970 | 0.81 | ALDH1A1 (0.61) | HPGDMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL3152055 | 0.81 | MAPT (0.47) | HPGDMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL28631519 | 0.81 | MAOB (0.45) | HPGDMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL390179 | 0.80 | ALOX5 (0.71) | HPGDMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL10886054 | 0.80 | IDH1 (0.70) | HPGDMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL9173452 | 0.80 | IDH1 (0.70) | HPGDMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL10558399 | 0.80 | MEN1 (0.67) | HPGDMEN1CYP3A4ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59216896-A | — | — | None | — | — | JP | disclosed |
| US-20240239761-A1 | BICYCLIC PHENOL COMPOUNDS AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4310077-A1 | BICYCLIC PHENOL COMPOUNDS AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-116693580-A | Anthracene skeleton phenol oxygen single metallocene bimetallic catalyst, preparation method and application | 万华化学集团股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2021262684-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20110105608-A1 | MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING | NORTHEASTERN UNIVERSITY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105608-A1 | MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING | NORTHEASTERN UNIVERSITY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105608-A1 | MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING | NORTHEASTERN UNIVERSITY (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2009117739-A1 | MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING | NORTHEASTERN UNIVERSITY (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117739-A1 | MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING | NORTHEASTERN UNIVERSITY (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-1408986-A4 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050215563-A1 | Proteomimetic compounds and methods | YALE UNIVERSITY | 2005-09-29 | — | — | US | disclosed |
| US-6858600-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1408986-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-1081132-B1 | HYDROXAMIC ACID DERIVATIVES AND MEDICINAL UTILIZATION THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6610729-B1 | Inhibotors of TNF, antiinflammatory | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20030008882-A1 | Proteomimetic compounds and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002089738-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1081132-A1 | HYDROXAMIC ACID DERIVATIVES AND MEDICINAL UTILIZATION THEREOF | Welfide Corporation (JP) | 2001-03-07 | — | — | EP | disclosed |
| JP-S59216896-A | ORGANIC PHOSPHORIC ESTER AND INSECTICIDE AND ACARICIDE | SANKYO CO LTD | 1984-12-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008882-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | HPGD 3501/4885MEN1 3279/4885CYP3A4 4622/4885 |
| US-20110105608-A1 | MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING | ESRRB, ESRRA, ESRRG | HPGD 1753/4885MEN1 4713/4885CYP3A4 4199/4885 |
| US-20240239761-A1 | BICYCLIC PHENOL COMPOUNDS AND USE THEREOF | CYP3A43, CYP11B2, UGT2B7 | HPGD 538/4885MEN1 4141/4885CYP3A4 35/4885 |
| US-20050215563-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | HPGD 3501/4885MEN1 3279/4885CYP3A4 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.